Cortexolone 17α-propionate powder (19608-29-8) hplc≥98% | AASraw
AASraw produces Cannabidiol(CBD) powder and Hemp Essential Oil in bulk!

Cortexolone 17α-propionate powder

Rating: SKU: 19608-29-8. Category:

AASraw is with synthesis and production ability from gram to mass order of Cortexolone 17α-propionate powder (19608-29-8) , under CGMP regulation and trackable quality control system.

Product Description


Cortexolone 17α-propionate powder video




Cortexolone 17α-propionate powder basic Characters


Name: Cortexolone 17α-propionate powder
CAS: 19608-29-8
Molecular Formula: C24H34O5
Molecular Weight: 402.52
Melt Point:
Storage Temp: Room Temperature
Color: White to off-white powder powder



Cortexolone 17α-propionate cycle



CAS: 19608-29-8
Chemical Names: cortexolone-17α-propionate,
Other Names: CB-03-01, Winlevi powder, Breezula powder, 11-deoxycortisol 17α-propionate, Cortexolone 17α-propionate powder


Cortexolone 17α-propionate Usage

Cortexolone 17α-propionate is a synthetic steroidal antiandrogen – specifically, an androgen receptor antagonist – that is under development by Cassiopea and Intrepid Therapeutics for use as a topical medication in the treatment of androgen-dependent conditions including acne vulgaris and androgenic alopecia (male-pattern hair loss).


What is the dosage of Cortexolone 17α-propionate

Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream.


Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17α-propionate is a new potent topical antiandrogen potentially useful in acne vulgaris.


To evaluate the safety and the topical efficacy of Cortexolone 17α-propionate 1% cream in acne vulgaris as compared with placebo and with tretinoin 0·05% cream.


Seventy-seven men with facial acne scored 2-3 according to Investigator’s Global Assessment (IGA) were randomized to receive placebo cream (n = 15), or Cortexolone 17α-propionate 1% cream (n = 30), or tretinoin 0·05% cream (n = 32) once a day at bedtime for 8 weeks. Clinical efficacy was evaluated every 2 weeks including total lesion count (TLC), inflammatory lesion count (ILC), acne severity index (ASI) and IGA. Safety assessment included local irritancy score, laboratory tests, physical examination, vital signs and recording of adverse events.


CB-03-01 cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0·0017), ILC (P = 0·0134) and ASI (P = 0·0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters. CB-03-01


This pilot study supports the rationale for the use of topical antiandrogens in the treatment of acne vulgaris. Cortexolone 17α-propionate 1% cream seems to fit with the profile of an ideal antiandrogen for topical use.


How Cortexolone 17α-propionate works

Cortexolone 17α-propionate(CAS 19608-29-8), or 11-deoxycortisol 17α-propionate, is a synthetic steroidal antiandrogen – specifically, an androgen receptor antagonist – that is under development by Cassiopea and Intrepid Therapeutics for use as a topical medication in the treatment of androgen-dependent conditions including acne vulgaris and androgenic alopecia (male-pattern hair loss). It is the C17α propionate ester of 11-deoxycortisol (cortexolone); C17α esters of 11-deoxycortisol were unexpectedly found to possess antiandrogen activity, and cortexolone 17α-propionate was selected for development based on its optimum drug profile.

In rats, the drug has been found to possess strong local antiandrogen activity, but negligible systemic antiandrogen activity when administered via subcutaneous injection. In addition, cortexolone 17α-propionate is not progonadotropic, suggesting that it is peripherally selective. In a bioassay, the topical potency of the drug was greater than that of progesterone, flutamide, and finasteride and was equivalent to that of cyproterone acetate.

A pilot clinical trial in 2011 of men treated with topical cortexolone 17α-propionate 1% cream for acne found that the drug was very well-tolerated and significantly reduced symptoms of acne. Moreover, its effectiveness was significantly greater than that of the active comparator, tretinoin 0.05% cream. As of 2017, the drug is in phase III clinical trials for acne vulgaris and phase II clinical trials for androgenic alopecia.



Cortexolone 17α-proprionate,Breezula powder  in its polymorphic forms: the first patent family, expiring in United States in 2022/23 and in 2022 in the rest of the world, covers the medical use of the compound for the treatment of acne, alopecia and other diseases; the second patents family covers all the known crystalline forms of the API, the compositions containing the same API and the related medical use in treating acne, AGA and other diseases: this patent family is already issued in United States, Europe, Canada, Japan and other countries, will expire in 2030 in United States and 2028 in the rest of the world.Breezula powder


Cortexolone 17α-propionate Raw Powder

Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order can be sent out in 3 working days after payment.


Cortexolone 17α-propionate Raw Powder Recipes

To inquiry our Customer Representitive(CSR) for details, for your reference.Winlevi powder


Cortexolone 17α-propionate Marketing

To be provided in the coming future.


Does Cortexolone 17α-propionate Have Any Side Effects

Cortexolone 17α-propionate is a new steroidal-ester, peripherally selective androgen-antagonist, endowed with mild antiinflammatory activity, that seems uniquely suited for the treatment of acne vulgaris. CB-03-01 acts at the human androgen-receptor level without inhibiting 5α-reductase in the skin. The steroid easily penetrates human skin and is quickly metabolized to free parent cortexolone which is devoid of systemic effects. Importantly, to date, has not demonstrated any local or systemic steroid side effects.



How to buy Cortexolone 17α-propionate powder from AASraw


1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.